

Adherium reports positive US pilot progress with disease management specialist HGE Health

Melbourne, Australia – 4 November 2020: Adherium Limited (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, is pleased to report progress with its Pennsylvania based disease management partner HGE Health in evaluating Adherium's Hailie[®] medication monitoring technology and data management solution in conjunction with HGE Health's HGE Care[™] platform in COPD patients.

HGE Health and Adherium have identified and started the engagement with 178 COPD patients who participate in the HGE Care[™] platform, to pilot the evaluation of Adherium's remote patient monitoring solution, using Hailie[®] sensors to track inhaled medication use and adherence. In the initial phase, the Hailie[®] technology is configured to passively track patients rescue medication, providing data on a regular basis to HGE's clinical care team. These data, in conjunction with the self-reported symptom data collected through HGE Care[™], allows the clinical team to assess if further intervention is required to manage the risk of an impending exacerbation, with a view to preventing unnecessary ER visits and hospitalisations and the associated cost.

"I am pleased to confirm the pilot programme planned with one of our two new commercial partners, HGE Health, is progressing well. Early data is enabling us to better understand the operational model required for success in this patient population including the benefits of linking technology with "humanware" [patient interaction directly with clinical staff] ensuring patient engagement with the technology and feeling it is personalized to them individually" said Mike Motion, CEO of Adherium. "The pilot is designed to identify differences in managing a patient population in a remote setting versus those in clinical trials or supported by hospital-based teams. This includes new patient enrollment protocols adapted to this setting and the development of materials for both patients and HGE's clinical co-ordinators which will support future scaling of the service. In addition, working with HGE and our innovation partner Planet Innovation, system upgrades have been implemented to improve the user interface and experience in this generally more aged population where the design of seemingly simple activities such as password entry and the pairing of devices needs careful thought.

In the next phase of the pilot, Adherium and HGE will introduce Hailie[®] sensors to monitor the use of patient preventer medication, which in combination with monitoring rescue medication use, will provide an even more complete picture of the patient's medication use and adherence. The current pilot is the at the first stage of evaluation ahead of scaling into commercialization in Q2 2021" added Mr. Motion.

"By introducing Adherium's Hailie[®] solution and HGE's Health Technology platform to a carefully selected group of COPD patients already on service, we will have further means of identifying patients potentially at risk of exacerbation by monitoring their medication dose and frequency of use and adherence." Dr. Mike Markus added, "Together we are learning the value of this information in the overall care of COPD patients, and operationally identifying what we need to implement to scale-up to a broader patient group. Improving patients' quality of life, responding early to changes in their day-to-day symptoms, minimizing the need for inpatient admissions due to acute exacerbations and reducing utilization costs".



About Adherium (ASX: ADR)

Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 170,000 sold globally. The Company develops, manufactures and supplies a broad range of connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Adherium's Hailie® solution is designed to help patients achieve better adherence and provide visibility to parents and caregivers. It does this by tracking medication use and reminding the user with helpful nudges when it is time to take doses, and by providing access to usage history to better understand patterns in their asthma and COPD.

Adherium has a series of new asthma and COPD sensors in development which, with their existing capabilities, will also enable the capture of physiological measures enabling access to CPT reimbursement for remote patient monitoring in the US. The first of these sensors are targeted for launch in the US in H1 calendar 2021.

These tools ultimately enable patients, with their physicians, to more effectively manage their Asthma and COPD and at the same time as potentially deliver significant healthcare cost savings to payors and providers.

Learn more at adherium.com.

About HGE Health

Headquartered in Fort Washington, PA, HGE Health harnesses its deep experience in chronic disease management and digital health in pulmonary disease, telemedicine, and mobile health to develop a clinical services platform that delivers better care faster at a much lower cost for patients, physicians and payors. Built on clinical protocols developed and supported by 16 years of research, the company's technology has compiled the longest-running and world's largest longitudinal data set of COPD symptoms, interventions, and clinical management to help physicians provide care for a geographically and socio-economically diverse COPD and pulmonary patient population.

The release of this announcement was authorised by the Adherium Board of Directors.

Enquiries:	Rudi Michelson Monsoon Communications +61 3 9620 3333 +61 (0)411 402 737 rudijohnmichelson@gmail.com	Mike Motion CEO Adherium +44 7917 688801 investors@adherium.com
-------------------	---	---